An International Network to Launch Clinical

Antiphospholipid Syndrome Studies Worldwide

 

Antiphospholipid Syndrome is a life-threatening autoimmune disorder in which your immune system mistakenly produces antibodies against certain normal proteins in your blood – causing blood clots within your arteries or veins as well as pregnancy complications, such as miscarriages and stillbirths. Please click here to learn more about APS.

 

It is a leading cause of stroke in young people, responsible for 1 out of 3 strokes in people under 50, 1 out of 5 recurrent miscarriages, and up to 20% of all deep-vein blood clots (DVT).

APS ACTION is a network of internationally renown physicians and scientists that works to find a cure for Antiphospholipid Syndrome. Members of the founding committee for APS ACTION include the list below (for the full membership list, please visit the “leadership & members” section”).

♦ Founding Members 

Laura Andreoli

University of Brescia,
Brescia, Italy

Ware Branch

University of Utah School of
Medicine, Salt Lake City, UT, USA

Ricard Cervera

Hospital Clinic, Barcelona,
Catalonia, Spain

Hannah Cohen

University College London
Hospitals, London, UK

Maria Cuadrado

St. Thomas Hospital,
London, England

Philip deGroot

University Medical Centre,
Utrecht, Netherlands

Ronald Derksen

University Medical Centre,
Utrecht, Netherlands

Doruk Erkan

Hospital for Special Surgery,
New York, NY, USA

Paul Fortin

Centre Hospitalier Universitaire
de Quebec, Quebec, Canada

Bill Giannakopoulos

St. George Hospital, University
of New South Wales,
Sydney, Australia

Munther Khamashta

St. Thomas Hospital,
London, England

Steve Krilis

St. George Hospital, University
of New South Wales,
Sydney, Australia

Steven R. Levine

SUNY Health Science Center, Downstate Stroke Center,
Brooklyn, NY, USA

Roger Levy

Universidade do Estado do
Rio de Janeiro, Brazil

Michael Lockshin

Hospital for Special Surgery,
New York, NY, USA

Pierluigi Meroni

University of Milan,
Milan, Italy

Tom Ortel

Duke University Medical Center,
Durham, NC, USA

Vittorio Pengo

University Hospital,
Padova, Italy

Silvia Pierangeli

University of Texas Medical Branch, Galveston, Texas, USA

Guillermo Pons-Estel

Hospital Clínic, Barcelona,
Catalonia, Spain

Jacob Rand

Weill Cornell Medicine,
New York, NY, USA

Robert Roubey

University of North Carolina,
Chapel Hill, NC, USA

Jane Salmon

Hospital for Special Surgery,
New York, NY, USA

Angela Tincani

University of Brescia,
Brescia, Italy

Denis Wahl

Nancy University,
Nancy, France

Click here to see
the full membership list

♦ Our Mission

 

PRIMARY MISSION:

To prevent, treat, and cure antiphospholipid antibody (aPL) associated clinical manifestations through high-quality, multicenter, and multidisciplinary clinical research.

 

SECONDARY MISSION:

To refine and advance the definitions of aPL associated clinical manifestations through international collaboration and data sharing.

 

APPROACH:

Members are working together to create a research alliance that will design and conduct clinical trials, and collect data via an international registry.

♦ How Did APS ACTION Start?

 

The Antiphospholipid Syndrome (APS) Clinical Research Task Force (CRTF) was one of six task forces developed by the organization committee of the 13th International Congress on Antiphospholipid Antibodies (aPL), which was held in Galveston, Texas in April 2010.

The task force recommended that there is an urgent need for a true international collaborative approach to design and conduct well-designed prospective large-scale multi-center clinical trials of patients with persistent and clinically significant aPL profiles1.

Thus, an international collaborative working meeting took place in Miami (Nov 2-4, 2010) that resulted in the formation of a clinical trial research alliance entitled: AntiPhospholipid Syndrome Alliance For Clinical Trials and InternatiOnal Networking (“APS ACTION”).2,3

1Erkan D, Derksen R, Levy R, Machin S, Ortel T, Pierangeli S, Roubey R, Lockshin MD. Antiphospholipid Syndrome Clinical Research Task Force Report. Lupus 2011;20:219

2Erkan D, Lockshin MD. APS ACTION. Lupus 2012;21:695.

3Barbhaiya M, Andrade D, Erkan D on Behalf of APS ACTION. APS ACTION 5-year Update. Curr Rheumatol Rep 2016;18:64.